Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study

Authors :: Vincenzo Nasillo
Elisabetta Lugli
Valeria Pioli
Laura Arletti
Paola Bresciani
Monica Maccaferri
Valeria Coluccio
Elisabetta Colaci
Mario Luppi
Andrea Messerotti
G. Ceccherelli
Maria Teresa Mariano
Angela Cuoghi
Ambra Paolini
Ivana Lagreca
Franco Narni
Chiara Quadrelli
Valeria Fantuzzi
Daniele Campioli
Giovanni Riva
Andrea Gilioli
Patrizia Barozzi
Leonardo Potenza
Roberto Marasca
Patrizia Comoli
Fabio Forghieri
Patrizia Zucchini
Tommaso Trenti
Daniela Vallerini
Monica Morselli
Source :: Leukemialymphoma. 59(1)
Publication Year :: 2017
Abstract: Biosimilars of filgrastim have shown to be comparable to the originator (Neupogen®, Amgen Inc., CA) in terms of pharmacodynamic response in healthy subjects, as well as in overall efficacy and safe...

Subjects :: Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
Filgrastim
030204 cardiovascular system & hematology
acute myeloid leukemia
Single Center
Biosimilars, filgrastim, autologous peripheral blood stem cell mobilization, acute myeloid leukemia
Transplantation, Autologous
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Hematologic Agents
medicine
Humans
Biosimilar Pharmaceuticals
Retrospective Studies
Biosimilars
Peripheral Blood Stem Cell Transplantation
business.industry
Myeloid leukemia
Biosimilar
Retrospective cohort study
Hematology
Middle Aged
medicine.disease
Hematopoietic Stem Cell Mobilization
Transplantation
Leukemia
autologous peripheral blood stem cell mobilization
Treatment Outcome
Leukemia, Myeloid
030220 oncology & carcinogenesis
Pharmacodynamics
Acute Disease
Peripheral Blood Stem Cells
Female
business
filgrastim
medicine.drug

Tools